Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01836536 : Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patients with histologically proved recurrent glioblastoma or anaplasic glioma,

- Tumor recurrence documented by MRI at least 3 months after the end of radiotherapy or
chemotherapy.

- Patients for whom a treatment by bevacizumab is proposed by a multidisciplinary team
staff.

- Age ? 18.

- Signed informed consent.

- Affiliation to a social security coverage

Exclusion Criteria:

- Known Hepatitis B or C or HIV.

- Inclusion in another clinical trial.

- Patient having received an anti-angiogenic therapy.

- Pregnant or breast-feeding woman.

- Person deprived of liberty or under guardianship or trusteeship or judicial
protection

- Inability to give informed consent

- Person unable or unwilling to comply with the requirements of the protocol for
geographical, social or psychological reasons.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01836536      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740